Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Neuralink's N1 Implant trial by end of 2025?
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Official trial results published by Neuralink or regulatory bodies
Elon Musk's Neuralink Launches Trial for N1 Implant to Control Assistive Robotic Arm
Nov 25, 2024, 06:14 PM
Neuralink, the brain-computer interface (BCI) company founded by Elon Musk, has announced the approval and launch of a new feasibility trial. The trial will test the use of Neuralink's N1 Implant to control an assistive robotic arm. This marks an important first step in the development of brain-computer interfaces, with the potential to restore both digital and physical freedom for individuals with disabilities.
View original story
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trial not completed • 25%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Achieves full sensory feedback • 25%
Enables multi-device control • 25%
Significant AI integration • 25%
Other • 25%
Significant improvement in vision • 25%
Moderate improvement in vision • 25%
No noticeable improvement • 25%
Negative side effects • 25%
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
Assistive technology for paralysis • 25%
Cognitive enhancement • 25%
Medical treatment for neurological disorders • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful due to technical issues • 25%
Unsuccessful due to patient complications • 25%
No • 50%
Yes • 50%
0 • 25%
More than 10 • 25%
6-10 • 25%
1-5 • 25%